Vivos raises $1M in Regulation A+ offering as it eyes Mayo Clinic trial
What's the deal? Vivos Inc.Dealroom has a profile for this one. Try Dealroom → disclosed on November 5, 2026, that it completed three unregistered equity transactions on October 30, raising $1 million in gross proceeds. The money, from a best-efforts Regulation A+ offering, is earmarked for general working capital.
The details: The company sold 12,500,000 common shares at a par value of $0.001 each. It also issued warrants to buy 25,000,000 shares to accredited investors for $25,000, exercisable at $0.075 and expiring December 31, 2030. A third transaction exchanged 8,000,000 new shares for the cancellation of 8,000,000 existing warrants.
What's the endgame? Vivos is advancing RadioGel toward a five-patient first-in-human feasibility study at Mayo ClinicDealroom has a profile for this one. Try Dealroom →, following FDA approval of its feasibility IDE in July. Its veterinary IsoPet business is also expanding.
Why now? The company has limited revenue and said in its second-quarter filing that it expected to need about $3 million annually. It flagged substantial doubt about its ability to continue without additional capital.
What could go wrong? The $1 million covers near-term execution but does not resolve the longer-term funding gap. The share and warrant issuances also dilute existing holders.
The signal: The raise is a step up for Vivos, but it is a modest one against its stated annual needs. For a clinical-stage company chasing a Mayo Clinic trial, repeated small financings keep the lights on while deferring the question of how to fund the path to market.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
